title: Interaction of a cyclic, bivalent smac mimetic with the x-linked inhibitor of apoptosis protein.
abstract: We have designed and synthesized a cyclic, bivalent Smac mimetic (compound 3) and characterized its interaction with the X-linked inhibitor of apoptosis protein (XIAP). Compound 3 binds to XIAP containing both BIR2 and BIR3 domains with a biphasic dose-response curve representing two binding sites with IC 50 values of 0.5 and 406 nM, respectively. Compound 3 binds to XIAPs containing the BIR3-only and BIR2-only domain with K i values of 4 nM and 4.4 microM, respectively. Gel filtration experiments using wild-type and mutated XIAPs showed that 3 forms a 1:2 stoichiometric complex with XIAP containing the BIR3-only domain. However, it forms a 1:1 stoichiometric complex with XIAP containing both BIR2 and BIR3 domains, and both BIR domains are involved in the binding. Compound 3 efficiently antagonizes inhibition of XIAP in a cell-free functional assay and is >200 times more potent than its corresponding monovalent compound 2. Determination of the crystal structure of 3 in complex with the XIAP BIR3 domain confirms that 3 induces homodimerization of the XIAP BIR3 domain and provides a structural basis for the cooperative binding of one molecule of compound 3 to two XIAP BIR3 molecules. On the basis of this crystal structure, a binding model of XIAP containing both BIR2 and BIR3 domains and 3 was constructed, which sheds light on the ability of 3 to relieve the inhibition of XIAP with not only caspase-9 but also caspase-3/-7. Compound 3 is cell-permeable, effectively activates caspases in whole cells, and potently inhibits cancer cell growth. Compound 3 is a useful biochemical and pharmacological tool for further elucidating the role of XIAP in regulation of apoptosis and represents a promising lead compound for the design of potent, cell-permeable Smac mimetics for cancer treatment.
authors: Department of Internal Medicine, Comprehensive Cancer Center, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, Michigan 48109, USA.
authors: Zaneta
authors: Z
authors: Nikolovska-Coleska
authors: Jennifer L
authors: JL
authors: Meagher
authors: Sheng
authors: S
authors: Jiang
authors: Chao-Yie
authors: CY
authors: Yang
authors: Su
authors: S
authors: Qiu
authors: Peter P
authors: PP
authors: Roller
authors: Jeanne A
authors: JA
authors: Stuckey
authors: Shaomeng
authors: S
authors: Wang
mesh_terms: D001665:Binding Sites; D040761:Biomimetic Materials / Q000138:chemical synthesis; D053148:Caspase 3 / Q000378:metabolism; D061945:Caspase Inhibitors; D002850:Chromatography, Gel; D018360:Crystallography, X-Ray; D004347:Drug Interactions; D005260:Female; D006801:Humans; D007700:Kinetics; D008024:Ligands; D008958:Models, Molecular; D017434:Protein Structure, Tertiary; D014407:Tumor Cells, Cultured; D051636:X-Linked Inhibitor of Apoptosis Protein / Q000037:antagonists & inhibitors / Q000378:metabolism*
chemical_list: D061945:Caspase Inhibitors; D008024:Ligands; D051636:X-Linked Inhibitor of Apoptosis Protein; C496866:XIAP protein, human; D053148:Caspase 3